- Home
- DFH vs SLNO Comparison
DFH vs SLNO Comparison
Compare DFH & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFH
- SLNO
- Stock Information
- Founded
- DFH 2008
- SLNO 1999
- Country
- DFH United States
- SLNO United States
- Employees
- DFH N/A
- SLNO N/A
- Industry
- DFH Homebuilding
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DFH Consumer Discretionary
- SLNO Health Care
- Exchange
- DFH Nasdaq
- SLNO Nasdaq
- Market Cap
- DFH 2.2B
- SLNO 1.9B
- IPO Year
- DFH 2021
- SLNO 2014
- Fundamental
- Price
- DFH $24.07
- SLNO $46.88
- Analyst Decision
- DFH Hold
- SLNO Strong Buy
- Analyst Count
- DFH 1
- SLNO 6
- Target Price
- DFH $38.00
- SLNO $74.83
- AVG Volume (30 Days)
- DFH 698.8K
- SLNO 567.7K
- Earning Date
- DFH 02-27-2025
- SLNO 03-05-2025
- Dividend Yield
- DFH N/A
- SLNO N/A
- EPS Growth
- DFH 15.80
- SLNO N/A
- EPS
- DFH 3.03
- SLNO N/A
- Revenue
- DFH $4,028,851,000.00
- SLNO N/A
- Revenue This Year
- DFH $15.56
- SLNO N/A
- Revenue Next Year
- DFH N/A
- SLNO N/A
- P/E Ratio
- DFH $7.97
- SLNO N/A
- Revenue Growth
- DFH 8.59
- SLNO N/A
- 52 Week Low
- DFH $21.42
- SLNO $36.61
- 52 Week High
- DFH $44.38
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- DFH 43.49
- SLNO 50.73
- Support Level
- DFH $23.34
- SLNO $41.50
- Resistance Level
- DFH $25.54
- SLNO $49.03
- Average True Range (ATR)
- DFH 0.98
- SLNO 2.31
- MACD
- DFH 0.41
- SLNO 0.47
- Stochastic Oscillator
- DFH 64.32
- SLNO 71.45
About DFH Dream Finders Homes Inc.
Dream Finders Homes Inc is engaged in the home building business. It designs, builds, and sells homes in Jacksonville, Orlando, Denver, the Washington D.C. metropolitan area, and Austin. The company operates through six geographical divisions namely, Jacksonville, Orlando, Denver, Washington DC (Capital), and the Carolinas (H&H Homes), Jet Home Loans LLC. Jacksonville division generates majority of the revenue for the firm.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.